ADU-1604

ADU-1604 is a humanized IgG1 monoclonal antibody that targets cytotoxic T‑lymphocyte‑associated protein 4 (CTLA-4), an immune checkpoint receptor expressed on T cells. By binding to a unique epitope on CTLA-4, ADU-1604 blocks the interaction of CTLA-4 with its ligands CD80 and CD86, thereby inhibiting the downregulation of T-cell activation. This results in enhanced cytotoxic T lymphocyte-mediated immune responses against cancer cells. Preclinical studies have shown that ADU-1604 is at least as potent as benchmark anti–CTLA‑4 antibodies such as ipilimumab and tremelimumab, with evidence for tumor growth inhibition and increased immunogenicity in animal models. In phase 1 clinical trials, it demonstrated dose-dependent pharmacodynamic effects on circulating CD4+ and CD8+ T cells in patients with advanced melanoma who relapsed or were refractory to prior anti–PD‑1/PD‑L1 therapy. The drug was originally developed by Aduro BioTech and has been further developed by Sairopa and Chinook Therapeutics[1][2][3][5][6][8].

Other names

Anti-CTLA4 antibodyAnti-CTLA-4 antibodyAnti-CTLA 4 antibody